Table 3 Clinical outcomes
Variables | TCD group | MAP group | Test of significance | P value |
|---|---|---|---|---|
Serum lactate (mmol/L) | ||||
Baseline | ||||
Median (IQR) | 3.80 (3.37 – 4.22) | 3.80 (3.45 – 4.20) | U 1545.50 | 0.896 |
End of NE infusion | ||||
Median (IQR) | 2.50 (2.14 – 5.80) | 2.65 (2.20 – 5.90) | U 1437.00 | 0.445 |
End of ICU stay | ||||
Median (IQR) | 1.98 (1.84 – 5.80) | 2.0 (1.86 – 5.90) | U 1549.50 | 0.914 |
SOFA score | ||||
Baseline | ||||
Median (IQR) | 4.0 (3.0 – 7.0) | 5.0 (3.0 – 8.0) | U 1378.50 | 0.260 |
End of ICU stay | ||||
Median (IQR) | 2.0 (1.0 – 11.0) | 2.0 (1.0 – 11.50) | U 1362.50 | 0.225 |
GCS | ||||
Baseline on ICU admission | ||||
Median (IQR) | 11.0 (10.0 –12.0) | 11.0 (9.0 – 12.0) | U 1392.50 | 0.301 |
Outcome at ICU discharge | ||||
Median (IQR) | 15.0 (8.0 –15.0) | 14.0 (5.0 – 15.0) | U 1169.50 | 0.014* |
ICU stay (days) | ||||
Median (IQR) | 6.0 (5.0 – 7.0) | 6.0 (5.0 – 7.0) | U 1419.50 | 0.379 |
ICU mortality | ||||
Percentage | 32.1 | 44.6 | χ2 1.850 | 0.174 |
Total NE dosing (mg) | ||||
Median (IQR) | 94.45 (65.85_248.0) | 113.5 (60.05_294.0) | U 1384.00 | 0.284 |
Duration of NE infusion (days) | ||||
Median (IQR) | 4.0 (3.0 – 7.0) | 5.0 (3.0 – 7.0) | U 1382.50 | 0.275 |